Universal screening at age 1-2 years as an adjunct to cascade testing for familial hypercholesterolaemia in the UK: A cost-utility analysis.

Cascade testing of relatives has been shown to be feasible, acceptable and cost-effective in the UK, but requires a supply of index cases. Feasibility of universal screening at age 1-2 years was also recently demonstrated. This paper examines whether this would be a cost-effective adjunct to Cascade testing, given the current and plausible future undiaganosed FH prevalence.

Source: Atherosclerosis

Read this article